Selective tuberous sclerosis complex 1 gene deletion in smooth muscle activates mammalian target of rapamycin signaling and induces pulmonary hypertension

American Journal of Respiratory Cell and Molecular Biology

Volumn 55, Issue 3, 2016, Pages 352-367

  Houssaini, Amal ^a,b   Abid, Shariq ^a,b   Derumeaux, Geneviève ^a,b   Wan, Feng ^a,b   Parpaleix, Aurélien ^a,b   Rideau, Dominique ^a,b   Marcos, Elisabeth ^a,b   Kebe, Kanny ^a,b   Czibik, Gabor ^a,b   Sawaki, Daigo ^a,b   Treins, Caroline ^c,d   Dubois Randé, Jean Luc ^a,b   Li, Zhenlin ^e   Amsellem, Valérie ^a,b   Lipskaia, Larissa ^a,b   Pende, Mario ^c,d   Adnot, Serge ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c INSTITUT NECKER ENFANTS MALADES   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e SORBONNE UNIVERSITÉ   (France)

Author keywords

Pulmonary hypertension; Rapamycin; Smooth muscle

Indexed keywords

CRE RECOMBINASE; GLYCOGEN SYNTHASE KINASE 3; INITIATION FACTOR 4E BINDING PROTEIN; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PF 478671; PROTEIN; PROTEIN SERINE THREONINE KINASE INHIBITOR; RAPAMYCIN; S6 KINASE; TUBEROUS SCLEROSIS COMPLEX 1 PROTEIN; UNCLASSIFIED DRUG; ACTIN BINDING PROTEIN; METFORMIN; MUSCLE PROTEIN; RIBOSOMAL PROTEIN S6 KINASE, 90KDA, POLYPEPTIDE 3; TAGLN PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE; TUMOR SUPPRESSOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL CULTURE; CONTROLLED STUDY; GENE; GENE DELETION; LOW DRUG DOSE; LUNG BLOOD VESSEL; MALE; MOUSE; NONHUMAN; PROMOTER REGION; PULMONARY ARTERY; PULMONARY HYPERTENSION; SMOOTH MUSCLE CELL; ANIMAL; CELL PROLIFERATION; CHRONIC DISEASE; COMPLICATION; DIAGNOSTIC IMAGING; DRUG EFFECTS; HYPERPLASIA; HYPOXIA; LUNG; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE; VASCULARIZATION;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; CHRONIC DISEASE; GENE DELETION; HYPERPLASIA; HYPERTENSION, PULMONARY; HYPOXIA; LUNG; MALE; METFORMIN; MICE; MICROFILAMENT PROTEINS; MUSCLE PROTEINS; MUSCLE, SMOOTH; MYOCYTES, SMOOTH MUSCLE; PULMONARY ARTERY; RIBOSOMAL PROTEIN S6 KINASES, 90-KDA; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84988978605     PISSN: 10441549     EISSN: 15354989     Source Type: Journal    
DOI: 10.1165/rcmb.2015-0339OC     Document Type: Article

References (25)

1. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, Weissmann N, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:S20-S31.
2. Abid S, Houssaïni A, Mouraret N, Marcos E, Amsellem V, Wan F, Dubois-RandéJL, Derumeaux G, Boczkowski J, Motterlini R, et al. P21-dependent protective effects of a carbon monoxide-releasing molecule-3 in pulmonary hypertension. Arterioscler Thromb Vasc Biol 2014;34:304-312.
3. Adnot S. Lessons learned from cancer may help in the treatment of pulmonary hypertension. J Clin Invest 2005;115:1461-1463.
4. Iwasaki H, Eguchi S, Ueno H, Marumo F, Hirata Y. Endothelinmediated vascular growth requires p42/p44 mitogen-activated protein kinase and p70 S6 kinase cascades via transactivation of epidermal growth factor receptor. Endocrinology 1999;140: 4659-4668.
5. Liu Y, Fanburg BL. Serotonin-induced growth of pulmonary artery smooth muscle requires activation of phosphatidylinositol 3-kinase/ serine-threonine protein kinase B/mammalian target of rapamycin/ p70 ribosomal S6 kinase 1. Am J Respir Cell Mol Biol 2006;34: 182-191.
6. Foster KG, Fingar DC. Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony. J Biol Chem 2010;285: 14071-14077.
7. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012;149:274-293.
8. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-484.
9. Goncharov DA, Kudryashova TV, Ziai H, Ihida-Stansbury K, DeLisser H, Krymskaya VP, Tuder RM, Kawut SM, Goncharova EA. Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension. Circulation 2014;129: 864-874.
10. Houssaini A, Abid S, Mouraret N, Wan F, Rideau D, Saker M, Marcos E, Tissot CM, Dubois-RandéJL, Amsellem V, et al. Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension. Am J Respir Cell Mol Biol 2013;48:568-577.
11. Krymskaya VP, Snow J, Cesarone G, Khavin I, Goncharov DA, Lim PN, Veasey SC, Ihida-Stansbury K, Jones PL, Goncharova EA. mTOR is required for pulmonary arterial vascular smooth muscle cell proliferation under chronic hypoxia. FASEB J 2011;25:1922-1933.
12. Paddenberg R, Stieger P, von Lilien AL, Faulhammer P, Goldenberg A, Tillmanns HH, Kummer W, Braun-Dullaeus RC. Rapamycin attenuates hypoxia-induced pulmonary vascular remodeling and right ventricular hypertrophy in mice. Respir Res 2007;8:15.
13. Zhou H, Liu H, Porvasnik SL, Terada N, Agarwal A, Cheng Y, Visner GA. Heme oxygenase-1 mediates the protective effects of rapamycin in monocrotaline-induced pulmonary hypertension. Lab Invest 2006; 86:62-71.
14. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159-168.
15. Blagosklonny MV. Selective anti-cancer agents as anti-aging drugs. Cancer Biol Ther 2013;14:1092-1097.
16. Meikle L, Talos DM, Onda H, Pollizzi K, Rotenberg A, Sahin M, Jensen FE, Kwiatkowski DJ. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci 2007;27: 5546-5558.
17. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007;67: 10804-10812.
18. Gary-Bobo G, Houssaini A, Amsellem V, Rideau D, Pacaud P, Perrin A, Brégeon J, Marcos E, Dubois-RandéJL, Sitbon O, et al. Effects of HIV protease inhibitors on progression of monocrotaline- and hypoxia-induced pulmonary hypertension in rats. Circulation 2010; 122:1937-1947.
19. Guignabert C, Izikki M, Tu LI, Li Z, Zadigue P, Barlier-Mur AM, Hanoun N, Rodman D, Hamon M, Adnot S, et al. Transgenic mice overexpressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 2006;98: 1323-1330.
20. Malhowski AJ, Hira H, Bashiruddin S, Warburton R, Goto J, Robert B, Kwiatkowski DJ, Finlay GA. Smooth muscle protein-22-mediated deletion of Tsc1 results in cardiac hypertrophy that is mTORC1-mediated and reversed by rapamycin. Hum Mol Genet 2011;20: 1290-1305.
21. Huang J, Dibble CC, Matsuzaki M, Manning BD. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol 2008;28:4104-4115.
22. Pollizzi K, Malinowska-Kolodziej I, Doughty C, Betz C, Ma J, Goto J, Kwiatkowski DJ. A hypomorphic allele of Tsc2 highlights the role of TSC1/TSC2 in signaling to AKT and models mild human TSC2 alleles. Hum Mol Genet 2009;18: 2378-2387.
23. Zhang HH, Lipovsky AI, Dibble CC, Sahin M, Manning BD. S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. Mol Cell 2006;24:185-197.
24. Hasty P, Livi CB, Dodds SG, Jones D, Strong R, Javors M, Fischer KE, Sloane L, Murthy K, Hubbard G, et al. eRapa restores a normal life span in a FAP mouse model. Cancer Prev Res (Phila) 2014;7:169-178.
25. Houghton PJ, Huang S. mTOR as a target for cancer therapy. Curr Top Microbiol Immunol 2004;279:339-359.